Chemomab Therapeutics Ltd.

NasdaqCM CMMB

Chemomab Therapeutics Ltd. Market Capitalization on January 14, 2025: USD 35.83 M

Chemomab Therapeutics Ltd. Market Capitalization is USD 35.83 M on January 14, 2025, a 368.81% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Chemomab Therapeutics Ltd. 52-week high Market Capitalization is USD 48.18 M on January 06, 2025, which is 34.48% above the current Market Capitalization.
Chemomab Therapeutics Ltd. 52-week low Market Capitalization is USD 7.00 M on January 26, 2024, which is -80.47% below the current Market Capitalization.
Chemomab Therapeutics Ltd. average Market Capitalization for the last 52 weeks is USD 18.85 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: CMMB

Chemomab Therapeutics Ltd.

CEO	Dr. Adi Mor George Ph.D.
IPO Date	Feb. 12, 2019
Location	Israel
Headquarters	Building 7
Employees	20
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Key trends

Past 5 years